Delivery Order 36F79721D0239-36C24524N0639
Award Date
5/31/24
Potential Completion Date
6/3/24
Potential Value
$11K
Federal Agency
Veterans Integrated Service Network 5
Awardee
Travere Therapeutics, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92130, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Veterans Affairs (VA) has awarded a firm fixed price delivery order contract to Travere Therapeutics, Inc., a biopharmaceutical company that specializes in rare disease therapies. The contract, valued at $11,125.32, is for the supply of the pharmaceutical drug Thiola 100 mg. This delivery order is placed against Travere Therapeutics' Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with the VA. Travere Therapeutics also holds a $25 million Blanket...
This federal contract award was made by the Department of Veterans Affairs (VA) to Travere Therapeutics, Inc., a biopharmaceutical company specializing in rare disease therapies. The $212,584.00 firm fixed-price purchase order is for the delivery of pharmaceutical drugs, with a period of performance ending on September 30, 2025. Travere Therapeutics holds a Federal Supply Schedule (FSS) contract with the VA as well as two Blanket Purchase Agreements (BPAs) specifically covering the procurement...
This federal contract award to Travere Therapeutics, Inc. is for the delivery of the drug Thiola Tiopronin. The contract, valued at $11,125.32, is a firm fixed price delivery order issued against Travere's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with the U.S. Department of Veterans Affairs (VA). The award, which does not have a set-aside designation, has an ultimate completion date of August 26, 2024. Travere Therapeutics is a biopharmaceutical company specializing...
This federal contract award is a Delivery Order issued by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Travere Therapeutics, Inc. to provide the pharmaceutical drug THIOLA 100 MG. The contract is a firm fixed price award with a potential value of $11,125.32 and a performance period ending on April 24, 2024. The contract is issued under Travere Therapeutics' existing Pharmaceuticals and Drugs GSA Schedule contract. No set-aside was used for this award. Travere...
This is a federal contract award to Travere Therapeutics, Inc., a biopharmaceutical company, for the delivery of the pharmaceutical product Thiola 100 mg. The contract, valued at $11,125.32, was awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 5 (VISN 5) on August 26, 2024, with an ultimate completion date of August 27, 2024. The contract is a firm fixed price delivery order issued under Travere's Federal Supply Schedule (FSS) contract with the VA for...
This is a firm fixed price delivery order awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 7 to Travere Therapeutics, Inc. for the supply of the pharmaceutical drug Thiola. The delivery order, valued at $124,160.04, was issued under Travere Therapeutics' Pharmaceuticals and Drugs GSA Schedule contract. Travere Therapeutics is a biopharmaceutical company that provides specialty pharmaceuticals to government agencies, including the...
This federal contract award is for the delivery of Thiola 100 mg, a medication produced by Travere Therapeutics, Inc., a biopharmaceutical company specializing in rare disease therapies. The contract, valued at $11,125.32, was awarded by the Veterans Integrated Service Network 5 (VISN 5) of the Department of Veterans Affairs (VA) on July 25, 2024. It is a firm fixed-price delivery order contract, with a completion date of July 26, 2024. The contract is placed under Travere Therapeutics'...
This is a delivery order contract awarded by the Department of Veterans Affairs (VA) to Travere Therapeutics, Inc., a biopharmaceutical company specializing in rare disease therapies. The $32,838.56 firm fixed-price contract is for the supply of the drug Thiola (tiopronin) to the VA healthcare system. The contract is issued under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and does not utilize any set-aside designations, indicating open competition. Travere...
This is a firm fixed-price delivery order award to Travere Therapeutics, Inc., a biopharmaceutical company, by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 21. The contract is for the supply of Travere's specialty pharmaceutical product Filspari 400mg, which is used to treat rare diseases affecting kidney and liver function. The award has a ceiling value of $7,354.26 and a period of performance through September 30, 2024. Travere Therapeutics holds a Federal Supply...
This is a federal contract award issued by the Veterans Integrated Service Network 20 (VISN 20) of the U.S. Department of Veterans Affairs (VA) to Travere Therapeutics, Inc. The contract is for the delivery of the pharmaceutical product Filspari, with a ceiling value of $11,280.64 and a completion date of December 18, 2024. The contract is a Delivery Order under Travere's Federal Supply Schedule (FSS) contract with the VA for Pharmaceuticals and Drugs (FSS-61-IB). Additionally, Travere holds two...